Physician profile
Jack Murciano
NPI 1013950104
$700.03
in general payments reported to CMS, 2019-2025
13 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.66 · 2020: $98.75 · 2022: $52.95 · 2023: $166 · 2024: $150 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473 · Long Term Medical Supply Or Device Loan: $42.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.43 |
| Long Term Medical Supply Or Device Loan | $42.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $140.78 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $132.70 | 2019-2025 | Vaxelis, Gardasil 9, Rotateq |
| Cranial Technologies, INC | $91.77 | 2022-2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $61.55 | 2023-2024 | Flumist Quadrivalent |
| Sanofi Pasteur INC. | $58.31 | 2023-2025 | |
| Alk-Abello, INC | $57.75 | 2025 | Neffy, Odactra, Grastek |
| Baxter Healthcare | $42.24 | 2024 | Hillrom - Spot Vision Screener |
| Acadia Pharmaceuticals INC | $24.00 | 2025 | Daybue |
| Ars Pharmaceuticals Operations, INC. | $21.60 | 2025 | Neffy |
| Pfizer INC. | $20.00 | 2024 | |
| Avion Pharmaceuticals | $18.33 | 2023 | Methylphenidate Hydrochloride |
| Galderma Laboratories, L.P. | $15.63 | 2022 | |
| Collegium Pharmaceutical, INC. | $15.37 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Murciano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.